As of November 6, 2026, ADC Therapeutics SA is a publicly traded company (NYSE: ADCT); its largest reported holder is Bain Capital Life Sciences Opportunities IV, L.P., with 9.99% on Schedule 13G of October 29, 2026, then Redmile Group, LLC (9.9%). The largest insider holding is Jeremy Green, a 10% owner, with 51,190,570 shares (40.1% of shares outstanding), per Form 4 of April 2, 2026 (Schedule 13G, October 29, 2026).
Is this your company?
About to sign with, pay or invest in ADC Therapeutics SA? See the free Snapshot first.
Free to see. No signup.
Is ADC Therapeutics SA a real, registered company?
- ADC Therapeutics SA files with the SEC under CIK 1771910 (its SEC filings).
- Its shares are listed under the ticker ADCT on NYSE (SEC company record).
- Incorporated in V8; business address in Epalinges, V8, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ADC Therapeutics SA in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Bain Capital Life Sciences Opportunities IV, L.P. (filed 2026-10-29).
Who are ADC Therapeutics SA's owners and officers?
ADC Therapeutics SA: business address in Epalinges, V8; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-29).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-29 | Bain Capital Life Sciences Opportunities Iv, L.P. | 9.99% |
| Schedule 13G, 2026-08-14 | Nantahala Capital Management, LLC | 9.69% |
| Schedule 13G, 2026-07-27 | Blackrock, Inc. | 5.4% |
| Schedule 13G/A, 2026-04-24 | Redmile Group, LLC | 9.9% |
| Schedule 13G/A, 2026-04-06 | Redmile Group, LLC | 9.9% |
| Schedule 13G/A, 2026-02-17 | Orbimed Capital LLC | 2.6% |
| Schedule 13G, 2026-02-17 | Tcg Crossover Gp Ii, LLC | 9.2% |
| Schedule 13G/A, 2026-02-17 | Point72 Asset Management, L.P. | 4% |
| Schedule 13G/A, 2026-02-17 | Redmile Group, LLC | 12.7% |
| Schedule 13G/A, 2026-02-13 | Prosight Management, LP | 6.8% |
| Schedule 13G/A, 2025-11-13 | Prosight Management, LP | 5.8% |
| Schedule 13G/A, 2025-11-05 | Oaktree Fund Administration, LLC | 4.14% |
Questions about who owns ADC Therapeutics SA
Who owns ADC Therapeutics SA?
On this page, 6 holders' latest ownership filings report 5% or more of ADC Therapeutics SA: Bain Capital Life Sciences Opportunities Iv, L.P. (9.99%, Schedule 13G, filed 2026-10-29), Redmile Group, LLC (9.9%, Schedule 13G/A, filed 2026-04-24), Nantahala Capital Management, LLC (9.69%, Schedule 13G, filed 2026-08-14), Tcg Crossover Gp Ii, LLC (9.2%, Schedule 13G, filed 2026-02-17) and Prosight Management, LP (6.8%, Schedule 13G/A, filed 2026-02-13); 1 more is listed above.
Who are the largest shareholders of ADC Therapeutics SA?
By the share each holder's latest filing reports, the largest holders of ADC Therapeutics SA on this page are Bain Capital Life Sciences Opportunities Iv, L.P. (9.99%), Redmile Group, LLC (9.9%) and Nantahala Capital Management, LLC (9.69%).
When did Bain Capital Life Sciences Opportunities Iv, L.P. buy into ADC Therapeutics SA?
The filings give report dates, not purchase dates. The earliest filing from Bain Capital Life Sciences Opportunities Iv, L.P. on this page is the Schedule 13G, filed 2026-10-29, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on ADC Therapeutics SA?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on ADC Therapeutics SA: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ADC Therapeutics SA covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own ADC Therapeutics SA shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 51,190,570 shares (40.1% of shares outstanding), 23,222,602 held directly and 27,967,968 indirectly, on a joint filing (Form 4, 2026-04-02).
- Redmile Group, LLC, a 10% owner: 51,190,570 shares (40.1% of shares outstanding), 23,222,602 held directly and 27,967,968 indirectly, on a joint filing (Form 4, 2026-04-02).
- RedCo II Master Fund, L.P., a 10% owner: 51,190,570 shares (40.1% of shares outstanding), 23,222,602 held directly and 27,967,968 indirectly, on a joint filing (Form 4, 2026-04-02).
- , a 10% owner: 9,788,944 shares (7.7% of shares outstanding) (Form 4, 2025-05-19).
- , the chief executive and a director: 2,121,769 shares (1.7% of shares outstanding) (Form 4, 2026-07-02).
Shares outstanding: 127,667,695 as of 2026-08-03, from the company's latest SEC cover page.
How much has ADC Therapeutics SA raised?
No fundraising or offering filing from ADC Therapeutics SA is on file with us.
Keep reading
More on ADC Therapeutics SA and the records around it.
ADC Therapeutics SA elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Bain Capital Life Sciences Opportunities IV, L.P. also filed stake reports on 1 other company: OLEMA PHARMACEUTICALS, INC. (May 2026)
- Oaktree Fund Administration, LLC also filed stake reports on 3 other companies: TORM plc (Jun 2026), ONITY GROUP INC. (Jan 2026)
- Prosight Management, LP also filed stake reports on 5 other companies: OnKure Therapeutics, Inc. (Aug 2026), MeiraGTx Holdings plc (Feb 2026), Janux Therapeutics, Inc. (Feb 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/adc-therapeutics-sa